Selective norepinephrine reuptake inhibitor and purpose thereof in preparation of medicament for attention deficit / hyperactivity disorder

Abstract

The invention relates to a compound, which can be used as a selective norepinephrine reuptake inhibitor, and a purpose thereof in preparation of medicaments for ADHD (attention deficit / hyperactivity disorder). Compared with a central nervous system stimulant methylphenidate, the compound of the invention will not induce twitch or worsen dyskinesia, has little side effect, and is more suitable for ADHD patients. In addition, ADHD medicaments prepared from the compound of the invention have small application dosage.

Description

technical field [0001] The present invention relates to a selective norepinephrine reuptake inhibitor and its use in preparing a drug for attention deficit hyperactivity disorder. Background technique [0002] Attention deficit / hyperactivity disorder (ADHD) mostly begins around age 3 years, often persists into adolescence and 60% persist into adults. Its main clinical features are distraction, hyperactivity and impulsive behavior, which can be manifested as difficulty in completing tasks, forgetting, low frustration tolerance, risky behavior, and often comorbid with a variety of mental disorders such as anxiety disorders, depressive disorders, and bipolar disorder. , antisocial personality disorder, substance abuse and dependence, etc., resulting in impaired life, work, and social functions of patients and huge medical and socioeconomic burdens. [0003] Drug therapy is the main treatment method for ADHD, and central stimulants (such as methylphenidate, dextroamphetamine) a...

AI Technical Summary

Problems solved by technology

Clinical practice has proved that central stimulants are safe and effective in the treatment of ADHD, but because of side effects such as insomnia, loss of appetite, tics, anxiety, irritability, palpitations, increased blood pressure, dysphonia and rebound, it is often necessary to

Images